SAN DIEGO - Neurocrine (NASDAQ:NBIX) Biosciences, Inc. (NASDAQ: NBIX) has recently introduced a new sprinkle formulation of INGREZZA® (valbenazine) capsules, designed to aid adults with tardive dyskinesia and chorea associated with Huntington's disease who have difficulty swallowing.
The new product, INGREZZA® SPRINKLE, is now available and can be obtained through the same specialty and local affiliated pharmacies that provide the original INGREZZA capsules.
The sprinkle formulation allows the medication to be added to soft foods like applesauce, yogurt, or pudding, making it easier for patients with swallowing issues to take their medication. According to Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences, this new option is intended to alleviate the challenge of swallowing capsules for patients and caregivers.
The U.S. Food and Drug Administration approved INGREZZA SPRINKLE on April 30, 2024, based on data demonstrating its bioequivalence and tolerability compared to the original INGREZZA capsules. The sprinkle version maintains the same simple dosing options (40 mg, 60 mg, and 80 mg) and is taken once daily without the need for complex dose adjustments.
Katie Jackson, President of Help 4 HD International, highlighted the importance of such a formulation for individuals with Huntington's disease, who often experience swallowing difficulties as the disease progresses.
The INBRACE® Support Program, provided by Neurocrine Biosciences, assists patients prescribed INGREZZA or INGREZZA SPRINKLE with product support and prescription fulfillment. The program also offers copay assistance for patients with commercial insurance, and those without prescription coverage and financial resources may qualify for patient assistance.
INGREZZA and its new sprinkle formulation are vesicular monoamine transporter 2 (VMAT2) inhibitors, which selectively inhibit VMAT2 without significant interaction with other receptors.
VMAT2 is involved in the regulation of dopamine, a neurotransmitter that influences movement. By reducing excessive dopamine signaling, INGREZZA is believed to mitigate uncontrollable movements associated with tardive dyskinesia and Huntington's disease chorea.
This news is based on a press release statement from Neurocrine Biosciences.
In other recent news, Neurocrine Biosciences has made significant strides in the pharmaceutical sector. The U.S. Food and Drug Administration (FDA) has accepted for Priority Review two New Drug Applications (NDAs) for Neurocrine Biosciences' crinecerfont, a potential new treatment for congenital adrenal hyperplasia (CAH).
The company also reported promising results from their CAHtalyst Pediatric and Adult Phase 3 studies, with crinecerfont meeting primary and key secondary endpoints in treating CAH.
RBC Capital maintained its Sector Perform rating on Neurocrine Biosciences, acknowledging factors such as the strong performance of the company's product and the anticipation of phase II data for a particular compound.
Meanwhile, Wells Fargo reiterated its Overweight rating on the company's shares, following the presentation of updated data on Neurocrine Biosciences' drug candidate, atumelnant.
Neurocrine Biosciences also announced the appointment of Kyle Gano, Ph.D., as the CEO-elect, set to take over in October 2024. Dr. Gano will succeed Kevin Gorman, Ph.D., the company's long-standing CEO who will retire but continue to serve on the Neurocrine Board of Directors.
InvestingPro Insights
Neurocrine Biosciences, Inc. (NASDAQ: NBIX), with its latest innovation in INGREZZA® SPRINKLE, not only expands treatment options for patients but also demonstrates the company's ongoing commitment to addressing unmet medical needs. As investors consider the prospects of Neurocrine Biosciences, several key metrics and insights from InvestingPro can provide a deeper understanding of the company's financial health and market performance.
InvestingPro Data highlights a robust revenue growth for the company, with a 23.99% increase in revenue over the last twelve months as of Q1 2024. This growth is indicative of the company's successful commercialization efforts and potential market expansion due to new product offerings like INGREZZA® SPRINKLE.
The P/E Ratio, a measure of a company's current share price relative to its per-share earnings, stands at 34.45 (adjusted), suggesting a higher market expectation of future earnings growth. This could reflect investor confidence in the company's pipeline and its ability to generate profits from its innovative treatments.
InvestingPro Tips for Neurocrine Biosciences include an anticipation of net income growth this year and the company's operation with a moderate level of debt. These indicators are essential for stakeholders to understand the company's potential to sustain its growth trajectory and manage its financial obligations effectively.
For those looking for more in-depth analysis, InvestingPro offers additional tips on the financial health and market performance of Neurocrine Biosciences. With a total of 13 InvestingPro Tips available, investors can gain a comprehensive view of the company's strategic position. To explore these tips further, visit https://www.investing.com/pro/NBIX and consider using the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription. This exclusive offer provides access to a wealth of financial data and expert insights that can inform investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.